Literature DB >> 24672569

A successful treatment of rhinocerebral mucormycosis due to Rhizopus oryzae.

Rasoul Mohammadi1, Mehdi Nazeri2, Sayed Mohammad Amin Sayedayn3, Hassan Ehteram4.   

Abstract

Mucormycosis is an invasive fungal infection caused by filamentous fungi of the Mucoraceae family. The genera most commonly responsible are Mucor or Rhizopus. The disease occurs mostly in association with diabetic ketoacidosis. Mucormycosis has an extremely high death rate even when aggressive surgery is done. Death rates range from 25-85% depending on the body area involved. A case of rhinocerebral mucormycosis in a 65-year-old diabetic male patient typically presenting as headache, especially in parietal and frontal lobes, with nose and left eye discharge. After clinical and laboratory examination, mucormycosis was diagnosed, and Rhizopus oryzae was isolated. Systemic therapy with amphotericin B administered intravenously then replaced by posaconazole by a combination of aggressive surgery. The patient was treated and followed up for one year. We emphasize the importance of early detection and aggressive treatment in the management of this fatal disease.

Entities:  

Keywords:  Diabetes; Rhizopus oryzae; rhinocerebral mucormycosis

Year:  2014        PMID: 24672569      PMCID: PMC3963327     

Source DB:  PubMed          Journal:  J Res Med Sci        ISSN: 1735-1995            Impact factor:   1.852


INTRODUCTION

Mucormycosis is a rare and potentially lethal infection. It is caused by one of the members of the Mucoraceae family, including the Absidia, Mucor, and Rhizopus which may be found in decaying food, in the soil, or other organic matter, such as animal excreta.[1] They have the ability to rapidly grow and release large numbers of spores that become airborne and gain entrance to the human body through inhalation or ingestion. However, it rarely causes an infection in one with an intact immune system which can phagocytize the spores.[2] Rhinocerebral mucormycosis is associated with immunocompromised patient state, hemochromatosis, desferrioxamine therapy, malignancy, diabetes mellitus with or without ketoacidosis, organ transplantation, severe burns, trauma and prolonged corticosteroid therapy.[3] Because rhinocerebral mucormycosis occurs infrequently it may pose a diagnostic and therapeutic problems for those who are not familiar with its clinical presentation. Early clinical recognition of this potentially fatal disease followed by aggressive debridement, systemic antifungal therapy, and control of underlying co-morbid factors is the mainstay of therapy.[4] In this presentation we report a rhinocerebral mucormycosis in a diabetic male he was treated after appropriate therapy.

CASE REPORT

A 65-year-old man with diabetes mellitus type 2 typically had headache (especially in parietal and frontal lobes), nose and the left eye discharge, was admitted in 2012 in Al-Zahara hospital in Isfahan, Iran. He had a fifteen-year's history of diabetes, hypertension, hyperlipoproteinemia, and kidneys dysfunction. He suffered from nightly headache even was not healed with opioid drugs such as morphine and methadone. Each episode of headache has been survived about four hours accompanied by nose and eye discharge. There was no fever, nausea, vomiting, dizziness, diplopia, blurred vision, and memory dysfunction. Proptosis of the left orbit occurred. Brain MRI found the left ethmoidal and maxillary sinusitis and subperiosteal abscess in left orbit. There was a signal change in the left frontal lobe as high signal intensity on T2 FLAIR with edema and minimal mass effect [Figure 1]. Endoscopy of the nose and paranasal sinuses was performed and sampling from tissue and discharges was done and then transferred to the clinical laboratory. Both culture results and the characteristic hyphae in sections [Figure 2] confirmed mucormycosis. The isolate was identified as Rhizopus oryzae by sequence analysis (Gene Bank accession number is KF228585). The patient was transferred to the Department of Otolaryngology (ENT) and amphotericin B (50 mg/day) was prescribed for him, and debridement of sphenoid sinus walls was performed. Because of renal failure of the patient, drug regimen changed to posaconazole (PCZ)(5 mg/kg). After 20 days, headache recommenced and brain MRI showed invasion to the frontal lobe. He was nominated for craniotomy surgery and finally enucleation of the left eye was accomplished. At last, after revision of paranasal sinuses for assurance of eradication of the disease, the patient was released from hospital with drug regimen of posaconazole (5 mg/kg) for two weeks. We followed up him for one year and he is still alive.
Figure 1

The brain MRI study with sagittal and coronal plane. There is a signal change in the left frontal lobe as high signal intensity on T2 FLAIR with edema and minimal mass effect, assymetry of the left orbit compared to the right side. Small vessel ischemia and maxillo-ethmoidal sinusitis are noticed

Figure 2

Broad and aseptate hyphae in necrotic tissue (H and E stain, ×40)

The brain MRI study with sagittal and coronal plane. There is a signal change in the left frontal lobe as high signal intensity on T2 FLAIR with edema and minimal mass effect, assymetry of the left orbit compared to the right side. Small vessel ischemia and maxillo-ethmoidal sinusitis are noticed Broad and aseptate hyphae in necrotic tissue (H and E stain, ×40)

DISCUSSION

Mucormycosis is primarily a disease of subjects with altered host defenses associated with the underlying conditions and predisposing factors such as diabetes mellitus, hematologic malignancies, chemotherapy, corticosteroid therapy, organ transplantation, and so on. Diabetic patients are predisposed to mucormycosis because of the decreased ability of their neutrophils to phagocytize and adhere to endothelial walls. High blood sugar level may also alter the ability of macrophages.[5] Rhizopus, Mucor, Absidia are the most common isolated from patients with mucormycosis. Rhizopus is responsible for about 90% of rhinocerebral mucormycosis as seen in our study. We reconfirmed our results using the sequence analysis (Gene Bank accession number is KF228585). The first case of mucormycosis was described in 1885 by Paltauf, who created the term mycosis mucorina.[6] Infection occurs following inhalation of spores of Mucorales into the oral and nasal mucosa. Their germination is preferred by low oxygen, high glucose, acidic medium and high iron levels.[7] In rhinocerebral mucormycosis, generally the infection starts in the nasal tissues and spreads by direct extension into the paranasal sinuses and then to the orbit. As seen in our case, the diabetic patient with poor controlled blood sugar who developed rhinocerebral mucormycosis typically presented with headache, nose and left eye discharge, edema, unilateral proptosis of left orbit. Because the disease provokes the diffuse tissue necrosis, the fungi can easily invade the wall of blood vessels, leading to thrombosis and tissue ischemia.[8] Imaging studies like Magnetic resonance imaging (MRI) are important to evaluate the extent of the disease. MRI can demonstrate soft tissue lesions better than CT scan, especially in diagnosis of cavernous sinus thrombosis. When the orbit is invaded, increased density of the orbital fat and venous gulping may be seen, similar to our case patient. In this patient, the infection began in the paranasal sinuses and progressed to the orbit and the brain. Definitive diagnosis requires identification of the fungus histologically in tissue specimens or recovery of the fungus by culture. Mucorales appear as irregularly shaped, broad (10-50 μm), aseptate hyphae with right-angle branching.[9] Treatment of rhinocerebral mucormycosis should consist of prompt control of hyperglycemia and ketoacidosis, aggressive surgical debridement of involved tissue, and administration of parenteral amphotericin B.[10] Renal functions are monitored to document the amphotericin B induced nephrotoxicity. This monitoring helped us to replace posaconazole instead of amphotericin B because of our patient's renal failure. Aggressive surgical debridement of all necrotic tissue until normal well-perfused bleeding tissue is ideal. Orbital evisceration is advised if ophthalmoplegia and loss of vision has occurred, so that we did.
  9 in total

Review 1.  Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives.

Authors:  Kyung J Kwon-Chung
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

2.  [Rhinocerebral mucormycosis: report on eight cases].

Authors:  Raquel Artal; Beatriz Agreda; Eduardo Serrano; José I Alfonso; Héctor Vallés
Journal:  Acta Otorrinolaringol Esp       Date:  2010-03-06

Review 3.  Common infections in diabetes: pathogenesis, management and relationship to glycaemic control.

Authors:  Anton Y Peleg; Thilak Weerarathna; James S McCarthy; Timothy M E Davis
Journal:  Diabetes Metab Res Rev       Date:  2007-01       Impact factor: 4.876

4.  Mucormycosis: four case reports.

Authors:  Lamia Ammari; Badreddine Kilani; Hanène Tiouiri; Fakher Kanoun; Ahmed Goubontini; Emna Mnif; Fayçal Zouiten; Emna Chaker; Taoufik Ben Chaabane
Journal:  Tunis Med       Date:  2008-02

Review 5.  Recent advances in the management of mucormycosis: from bench to bedside.

Authors:  Brad Spellberg; Thomas J Walsh; Dimitrios P Kontoyiannis; John Edwards; Ashraf S Ibrahim
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

Review 6.  Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment.

Authors:  R M Prabhu; R Patel
Journal:  Clin Microbiol Infect       Date:  2004-03       Impact factor: 8.067

7.  Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae.

Authors:  Jen Kok; Nicole Gilroy; Catriona Halliday; Ok Cha Lee; Daniel Novakovic; Patrick Kevin; Sharon Chen
Journal:  J Infect       Date:  2007-07-10       Impact factor: 6.072

8.  Rhinocerebral mucormycosis: case report.

Authors:  J F Onyango; J K Kayima; W O Owen
Journal:  East Afr Med J       Date:  2002-07

9.  Infections in patients with diabetes mellitus: A review of pathogenesis.

Authors:  Juliana Casqueiro; Janine Casqueiro; Cresio Alves
Journal:  Indian J Endocrinol Metab       Date:  2012-03
  9 in total
  8 in total

1.  Identification of Mucorales isolates from soil using morphological and molecular methods.

Authors:  A Ziaee; M Zia; M Bayat; J Hashemi
Journal:  Curr Med Mycol       Date:  2016-03

2.  Novel Secreted Peptides From Rhizopus arrhizus var. delemar With Immunomodulatory Effects That Enhance Fungal Pathogenesis.

Authors:  Sameh S M Soliman; Eman M El-Labbad; Ameera Abu-Qiyas; Bahgat Fayed; Alshaimaa M Hamoda; Ahmed M Al-Rawi; Salam Dakalbab; Abdel-Nasser A El-Shorbagi; Mawieh Hamad; Ashraf S Ibrahim; Mohammad G Mohammad
Journal:  Front Microbiol       Date:  2022-03-21       Impact factor: 5.640

Review 3.  Mucormycosis: A new threat to Coronavirus disease 2019 with special emphasis on India.

Authors:  Deganta Ghosh; Sagardeep Dey; Himanko Chakraborty; Sneha Mukherjee; Ankita Halder; Akash Sarkar; Pallab Chakraborty; Rajdeep Ghosh; Joy Sarkar
Journal:  Clin Epidemiol Glob Health       Date:  2022-03-19

4.  Mucormycosis - The deadly fungus - A case report with dental perspective.

Authors:  Rakashree Chakraborty; Divya Pandya; Priyanka Dausage; Ashmita K Chawla
Journal:  J Family Med Prim Care       Date:  2022-03-18

5.  Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an in silico perspective.

Authors:  Abdo A Elfiky
Journal:  Future Microbiol       Date:  2022-05-05       Impact factor: 3.553

6.  Transcontinental Dispersal of Nonendemic Fungal Pathogens through Wooden Handicraft Imports.

Authors:  Jason A Smith; Tania Quesada; Gideon Alake; Nicolas Anger
Journal:  mBio       Date:  2022-06-29       Impact factor: 7.786

Review 7.  Silkworm as an experimental animal for research on fungal infections.

Authors:  Yasuhiko Matsumoto; Kazuhisa Sekimizu
Journal:  Microbiol Immunol       Date:  2019-02-14       Impact factor: 1.955

Review 8.  Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.

Authors:  P Monika; M N Chandraprabha
Journal:  Mol Biol Rep       Date:  2022-02-02       Impact factor: 2.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.